Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 22, 20 December 2023
Open
Access | Article
Current therapy of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)
* Author to whom correspondence should be addressed.
Abstract
In recent years, with the rapid development of molecular immunology and related biotechnology, immunotherapy has made breakthrough progress in tumor treatment. The main object of this paper is the current clinical treatment of different lung cancer and their advantages and disadvantages. Through the literature review method, the latest and most standard treatment methods were selected and summarized. Studies have found that chemotherapy, especially platinum-based chemotherapy, is still the most effective means for lung cancer in clinical practice, and immunotherapy mainly relies on combination with chemotherapy to play a role. However, as a new treatment method, epidemic therapy is becoming increasingly mature, and compared with traditional chemotherapy, it has greater research and development potential and broader prospects. The research and development of immunotherapy will be the focus of the therapies for lung cancer in the future. Researchers need to tailor treatment methods based on the principles of individualized treatment to optimize the design and outcomes of clinical studies.
Keywords
SCLC, NSCLC, current therapy
References
1. Lin L, Li Z, Yan L, Liu Y, Yang H, Li H. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019. J Hematol Oncol. 2021 Nov 22;14(1):197.
2. Fu J, Fang S, Wen Y, Wang Y, Yin X, Wang D. The efficacy and safety of irinotecan combined with nedaplatin in the treatment of small cell lung cancer. J BUON. 2020 Jul-Aug;25(4):1707-1713.
3. Shang Nana. Clinical comparison of different first-line chemotherapy regimens in the treatment of brain metastases in small cell lung cancer [J]. Chinese medical engineering, 2021, 29(04):129-130.
4. Pan D, Hou M, Li H, Yu P, Liu J. Irinotecan plus cisplatin compared with etoposide plus cisplatin for small cell lung cancer: a randomized clinical trial. Zhongguo Fei Ai Za Zhi. 2006 Oct 20;9(5):443-6. PMID: 21176468.
5. CAI Kel, Xie Zhilong, Liu Yingao et al. Advances in molecular mechanisms of chemotherapy resistance in small cell lung cancer [J]. Hainan Medicine,2022,33(16):2145-2147.
6. Ormrod D, Spencer CM. Topotecan: a review of its efficacy in small cell lung cancer. Drugs. 1999 Sep;58(3):533-51.
7. Al-Salama ZT. Durvalumab: A Review in Extensive-Stage SCLC NCCCCC.Target Oncol. 2021 Nov;16(6):857-864. Epub 2021 Nov 3. Erratum in: Target Oncol. 2022 Jan;17(1):91.
8. Ready N, Farago AF, de Braud F, Atmaca A, Hellmann MD, Schneider JG, Spigel DR, Moreno V, Chau I, Hann CL, Eder JP, Steele NL, Pieters A, Fairchild J, Antonia SJ. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. J Thorac Oncol. 2019 Feb;14(2):237-244. Epub 2018 Oct 10.
9. Chen J, Wang J, Xu H. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis. Medicine (Baltimore). 2021 Apr 16;100(15):e25180.
10. Chen HL, Tu YK, Chang HM, Lee TH, Wu KL, Tsai YC, Lee MH, Yang CJ, Hung JY, Chong IW. Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma. Cancers (Basel). 2020 Dec 3;12(12):3629.
11. Wang Huaqing, CUI Xiuzhen, ZHANG Wanling, LIU Xianming, ZHANG Huilai. Effect of paclitaxel and cisplatin in the treatment of advanced non-small cell lung cancer (a clinical report of 52 cases)[J]. Chinese Oncology Clinic,2001,(12):35-36+40.
12. Lv L, Lv J. Clinical efficacy of cisplatin combined with docetaxel in the treatment of non-small cell lung cancer [J]. Journal of Clinical Rational Use of Medicine, 2019,15(04):107-110.
13. Akdeniz N, Küçüköner M, Kaplan MA, Urakçı Z, Karhan O, Sezgin Y, Bilen E, Ebinç S, Teke F, Laçin Ş, Alan Ö, Ercelep Ö, Işıkdoğan A, Yumuk PF. Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer. Int J Clin Oncol. 2020 Dec;25(12):2015-2024.
14. Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, Park K, Sakai H, Ohe Y, Nishio M, Audigier-Valette C, Burgers JA et.al First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. J Thorac Oncol. 2022 Feb;17(2):289-308. Epub 2021 Oct 12.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
- ISBN (Print)
- 978-1-83558-217-6
- ISBN (Online)
- 978-1-83558-218-3
- Published Date
- 20 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/22/20230952
- Copyright
- 20 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited